Phylum and genus balance scores, Microbiome Interpretation

If your result is high

A high deviation score (or "imbalanced" flag) means the sample differs from the lab's internal reference; it is not proof of clinical dysbiosis without context.

If your result is low

A "balanced" or in-range score means proximity to the vendor mean, not validated optimal ecology for that individual.

Notes

Validation data are rarely published per vendor. See Dysbiosis, Alpha diversity, and F:B ratio.

Phylum and genus balance scores are vendor-defined indexes that compress many taxonomic abundances into one “gut balance” or “health score”, often by measuring distance from a reference cohort’s mean profile at phylum or genus level. If your report shows 72% balanced, phylum imbalance detected, or a genus equilibrium index, you are looking at a statistical comparison to other customers or a curated database, not a clinically validated wellness endpoint.

These scores overlap with dysbiosis labels and F:B ratio lines but add proprietary weighting that varies by company. Without published validation, a “low balance” flag is sample-specific context, not a diagnosis.

How balance scores are constructed

Exact algorithms are trade secrets, but common patterns include:

Step	Typical approach	Limit
Taxonomic profiling	16S or shotgun → phylum/genus table	Resolution and database affect all downstream scores
Reference cohort	Mean or median profile of “healthy” customers or public data	Geography, diet, and age skew the reference
Distance metric	Euclidean, Bray-Curtis, or weighted index vs reference	Sensitive to rare taxa and sequencing depth
Thresholding	Flag if distance exceeds percentile cut-off	Cut-offs are internal, not guideline-backed
Composite label	May merge balance + diversity + opportunist rules	Double-counts the same taxonomic signal

Some panels weight “beneficial” genera (Bifidobacterium, Lactobacillus, Faecalibacterium) against “undesirable” buckets (Proteobacteria, opportunists). That embeds value judgments that research cohorts do not treat as universal optima, high Bifidobacterium after a prebiotic trial is not the same construct as high Bifidobacterium in a untreated IBS sample (Duvallet et al., 2017).

Cross-study re-analysis (Duvallet 2017) undercuts the logic further: on average ~51% of genus-level associations in individual disease datasets were genera linked to more than one disease. Clostridiales (especially Lachnospiraceae and Ruminococcaceae, home to Faecalibacterium, Roseburia, and related butyrate producers) were depleted across multiple sick cohorts; Lactobacillales were enriched across multiple diseases as a shared sickness/transit signal. A balance score that penalises Proteobacteria while rewarding Lactobacillus can double-count one ecological story (diarrhoea, antibiotics, fast transit) as both “bad” and “good” depending on the bucket.

Vendor bucket	Research pattern (Duvallet meta-analysis)	Score risk
“Beneficial” Firmicutes	Often depleted in IBD and general sickness, not high = healthy	False reassurance when Clostridiales are low
“Opportunistic” Proteobacteria	↑ in diarrhoea; also post-antibiotic	True bloom vs transit overlap
“Beneficial” Lactobacillus	↑ non-specifically in multiple diseases	Penalising low Lactobacillus misses context
Composite balance	Mixes disease-specific (e.g. CRC enrichment) with shared responders	One number hides conflicting biology

Disease-specific enrichment (e.g. Fusobacterium in colorectal cancer across studies) is rarer than shared depletion of health-associated Clostridiales. Balance algorithms that treat all deviation as one “imbalance” cannot separate those patterns.

Overlap with dysbiosis labels

Reports often show balance score, dysbiosis index, and low diversity together. They are related but not redundant:

Label	What it usually captures
Balance score	Distance from reference at chosen taxonomic rank
Dysbiosis flag	Often balance + opportunist rules + diversity (vendor-specific)
Alpha diversity	Richness/evenness within sample, one axis of ecology
F:B ratio	Two-phylum legacy summary (F:B ratio)

You can have “balanced” phylum scores with low diversity after antibiotics, or “imbalanced” genus scores driven by one dietary shift (e.g. sudden fiber increase) that is physiologically benign. See Dysbiosis for how the ecological term is used on panels versus in research.

High vs low on reports

Report display	Likely meaning	Common misread
High imbalance / low score	Deviation from vendor “healthy” centroid	Proof of illness or need for intervention
In-range / balanced	Within vendor tolerance band	Guaranteed optimal microbiome
Improving trend on retest	Profile moved toward reference	Clinical improvement without symptom change

Reference cohort effects dominate interpretation. A profile typical in East Asia may read “imbalanced” against a US-customer reference and vice versa (Rinninella et al., 2019). Retests are comparable only with same lab and pipeline (Retesting over time).

What cannot be inferred

Balance scores do not measure:

Cannot show	Better tool or page
Mucosal inflammation	Calprotectin, Gut inflammation markers
Barrier permeability	Clinical workup; Intestinal barrier
Small-intestinal overgrowth	Breath testing (SIBO)
Food intolerance	Elimination diet trials (FODMAPs)
Infection requiring antibiotics	Stool culture/PCR; Opportunistic lists

A surprising pattern on some reports is high balance score alongside persistent symptoms, the index tracks taxonomic similarity to a reference, not symptom mechanism. Functional disorders can coexist with a “balanced” stool profile.

What not to conclude from balance scores

If the report says…	Do not conclude…
Low balance / imbalanced	You have clinical dysbiosis requiring antimicrobials
High balance	No need to evaluate symptoms clinically
Score below “optimal”	Vendor threshold equals medical reference range
Balance improved after supplement	Symptom endpoint proven without separate tracking
Genus-level imbalance	Specific genus is pathogenic at that read level